PMID- 21251188
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20110519
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 107
IP  - 11
DP  - 2011 Jun
TI  - Adverse events from targeted therapies in advanced renal cell carcinoma: the 
      impact on long-term use.
PG  - 1722-32
LID - 10.1111/j.1464-410X.2010.09985.x [doi]
AB  - What's known on the subject? and What does the study add? The side-effect of 
      targeted agents is known. The clinician should be aware of the side-effects of 
      targeted agents and how to prevent/diminish them, particularly in sequential and 
      combination therapies. The aim of this review is to help physicians tailor 
      targeted treatments for advanced renal cell carcinoma to suit patient needs and 
      ensure maximum overall duration of response to therapy by providing a summary of 
      the frequency and time of onset of adverse events (AEs) and by raising awareness 
      of AE profiles. A PubMed literature search was performed, and papers on targeted 
      therapy-related AEs were reviewed. The frequency, severity and management of 
      targeted therapy-related AEs are discussed. Manageable AEs commonly reported with 
      all the approved targeted agents include: fatigue, gastrointestinal disorders 
      (diarrhoea, nausea, vomiting), hypertension, skin and subcutaneous tissue 
      disorders. Life-threatening AEs are less common than manageable AEs and are 
      usually class specific. Data suggest that long-term treatment with 
      well-established targeted agents does not result in increased or unexpected AEs. 
      Caution is required with regard to the long-term use of newer targeted agents for 
      which there are no long-term tolerability data or clinical experience. Studies 
      have reported that the type and frequency of observed AEs associated with 
      sequential tyrosine kinase inhibitor (TKI) use are similar to those reported in 
      the literature for TKI monotherapy. Having an awareness of the AE profiles of 
      targeted agents allows the development of effective management strategies. 
      Generally, more extensive clinical experience has accumulated, and AE profiles 
      are more predictable, for well-established targeted agents.
CI  - (c) 2011 THE AUTHOR; BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.
FAU - Kirkali, Ziya
AU  - Kirkali Z
AD  - Dokuz Eylul University, School of Medicine, Izmir, Turkey. ziya.kirkali@gmail.com
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110120
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Carcinoma, Renal Cell/*drug therapy/mortality/pathology
MH  - Clinical Trials, Phase III as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Delivery Systems/methods
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Molecular Targeted Therapy/adverse effects/*methods
MH  - Prognosis
MH  - Risk Assessment
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2011/01/22 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/01/22 06:00
PHST- 2011/01/22 06:00 [entrez]
PHST- 2011/01/22 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
AID - 10.1111/j.1464-410X.2010.09985.x [doi]
PST - ppublish
SO  - BJU Int. 2011 Jun;107(11):1722-32. doi: 10.1111/j.1464-410X.2010.09985.x. Epub 
      2011 Jan 20.